Ata uhi

Plasma Lipidomics Profiles Highlight the Associations of the Dual Antioxidant/Pro-oxidant Molecules Sphingomyelin and Phosphatidylcholine with Subclinical Atherosclerosis in Patients with Type 1 Diabetes

Here, we report on our study of plasma lipidomics profiles of patients with type 1 diabetes (T1DM) and explore potential associations. One hundred and seven patients with T1DM were consecutively recruited. Ultrasound imaging of peripheral arteries was performed using a high image resolution B-mode u...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Lidia Sojo (Author), Elena Santos-González (Author), Lídia Riera (Author), Alex Aguilera (Author), Rebeca Barahona (Author), Paula Pellicer (Author), Maria Buxó (Author), Jordi Mayneris-Perxachs (Author), Mercè Fernandez-Balsells (Author), José-Manuel Fer (Author)
Hōputu:	Pukapuka
I whakaputaina:	MDPI AG, 2023-05-01T00:00:00Z.
Ngā marau:	article
Urunga tuihono:	Connect to this object online.
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite

Deficiency of sphingomyelin synthase 1 but not sphingomyelin synthase 2 reduces bone formation due to impaired osteoblast differentiation
mā: Goichi Matsumoto, me ētahi atu.
I whakaputaina: (2019)

Sphingomyelin-Based Nanosystems (SNs) for the Development of Anticancer miRNA Therapeutics
mā: Surasa Nagachinta, me ētahi atu.
I whakaputaina: (2020)

Evaluation of subclinical atherosclerosis in chronic sinusitis patients
mā: Musa Çakıcı, me ētahi atu.
I whakaputaina: (2015)

Biomarkers of Subclinical Atherosclerosis in Patients with Autoimmune Disorders
mā: Elisabetta Profumo, me ētahi atu.
I whakaputaina: (2012)

Insulin resistance and its association to carotid subclinical atherosclerosis.
mā: Abdel del Busto Mesa, me ētahi atu.
I whakaputaina: (2011)

The Role of Noninvasive Imaging for Detection High Risk Patients with Subclinical Atherosclerosis
mā: Krasimira Hristova
I whakaputaina: (2016)

Imaging subclinical coronary atherosclerosis to guide lipid management, are we there yet?
mā: Pamela Piña, me ētahi atu.
I whakaputaina: (2023)

Metabolically healthy obesity and subclinical atherosclerosis in persons with spinal cord injury
mā: Eun Sun Yoon, me ētahi atu.
I whakaputaina: (2018)

Assessment of subclinical atherosclerosis in ankylosing spondylitis: correlations with disease activity indices
mā: F.M. Perrotta, me ētahi atu.
I whakaputaina: (2013)

Subclinical atherosclerosis in young patients with rheumatoid arthritis and low disease activity
mā: F. Ragni Alunni, me ētahi atu.
I whakaputaina: (2011)

Biochemical Markers of Subclinical Atherosclerosis in Patients with Type 2 Diabetes Mellitus
mā: Caridad Osorio Sosa, me ētahi atu.
I whakaputaina: (2022)

Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma
mā: Fatima Bilal, me ētahi atu.
I whakaputaina: (2019)

The Role of Circulating Regulatory T Cell Levels on Subclinical Atherosclerosis and Cardiovascular Risk Factors in Women with Systemic Lupus Erythematosus
mā: Mario García-Carrasco, me ētahi atu.
I whakaputaina: (2018)

Associations between insulin resistance indices and subclinical atherosclerosis: A contemporary review
mā: Drake A. Scott, me ētahi atu.
I whakaputaina: (2024)

Fasting glucose: a cardiometabolic indicator for subclinical atherosclerosis on excess weight adolescents
mā: Camila M. Medeiros, me ētahi atu.
I whakaputaina: (2024)

Relation between mean platelet volume and subclinical atherosclerosis in patients with metabolic syndrome
mā: Ali Rıza Gülcan, me ētahi atu.
I whakaputaina: (2014)

Assessment of subclinical atherosclerosis in psoriatic arthritis patients without clinically overt cardiovascular disease or traditional atherosclerosis risk factor
mā: Şule Apraş Bilgen, me ētahi atu.
I whakaputaina: (2018)

Partial molecular volumes of cholesterol and phosphatidylcholine in mixed bilayers
mā: Gallová J., me ētahi atu.
I whakaputaina: (2017)

Cardiovascular risk and subclinical atherosclerosis in first-degree relatives of patients with premature cardiovascular disease
mā: Diana N. Vikulova, me ētahi atu.
I whakaputaina: (2024)

Assessment of Subclinical Manifestations of Atherosclerosis of Coronary and Peripheral Arteries and Bone Strength Parameters in Women
mā: I. A. Skripnikova, me ētahi atu.
I whakaputaina: (2020)

Subclinical atherosclerosis in patients with psoriatic arthritis: a case-control study. Preliminary data
mā: M. Zanon, me ētahi atu.
I whakaputaina: (2011)

Carotid intima-media thickness as an indicator of subclinical atherosclerosis in systemic lupus erythematosus patients
mā: Asmaa A Abozeid, me ētahi atu.
I whakaputaina: (2021)

Evaluation of arterial stiffness and subclinical atherosclerosis in patients with Behçet's disease without cardiovascular involvement
mā: Alp Yıldırım, me ētahi atu.
I whakaputaina: (2016)

The association between serum hepcidin-25 level and subclinical atherosclerosis in peritoneal dialysis patients
mā: Bülent Erdoğan, me ētahi atu.
I whakaputaina: (2018)

Disease activity index is associated with subclinical atherosclerosis in childhood-onset systemic lupus erythematosus
mā: Priscila B. S. Medeiros, me ētahi atu.
I whakaputaina: (2021)

Insulin metabolism markers are predictors of subclinical atherosclerosis among overweight and obese children and adolescents
mā: Golaleh Asghari, me ētahi atu.
I whakaputaina: (2018)

Immune Activation, Immunosenescence, and Osteoprotegerin as Markers of Endothelial Dysfunction in Subclinical HIV-Associated Atherosclerosis
mā: Alessandra D'Abramo, me ētahi atu.
I whakaputaina: (2014)

Sphingomyelin phosphodiesterase-1 (SMPD1) coding variants do not contribute to low levels of high-density lipoprotein cholesterol
mā: Genest Jacques, me ētahi atu.
I whakaputaina: (2007)

Association of SOGPI in mediating the effect of Phosphatidylcholine on polycystic Ovary Syndrome
mā: Qian Guo, me ētahi atu.
I whakaputaina: (2024)

Ultramarathon Plasma Metabolomics: Phosphatidylcholine Levels Associated with Running Performance
mā: Tracy B. Høeg, me ētahi atu.
I whakaputaina: (2020)

Changes in Cardiovascular Health during Young Adulthood and Subclinical Atherosclerosis in Middle Age: The CARDIA Study
mā: Xiaomin Ye, me ētahi atu.
I whakaputaina: (2023)

Association between insomnia and subclinical atherosclerosis among Chinese steelworkers: a cross-sectional survey
mā: Lihua Wang, me ētahi atu.
I whakaputaina: (2022)

Relationship between parameters of subclinical atherosclerosis and osteoporosis and their prognostic significance: data from the prospective studies
mā: I. A. Skripnikova, me ētahi atu.
I whakaputaina: (2023)

The Value of Subclinical Carotid Atherosclerosis for Primary Prevention of Cardiovascular Diseases. Review of the Main International Studies
mā: E. K. Butina, me ētahi atu.
I whakaputaina: (2016)

Subclinical Atherosclerosis in Young Adult Population with First Degree Relatives of Type 2 Diabetes Mellitus
mā: Muhammad Syah Abdaly, me ētahi atu.
I whakaputaina: (2019)

Assessment of some inflammatory markers and lipid profile as risk factors for atherosclerosis in subclinical hypothyroid patients
mā: Khaled A El-Hefnawy, me ētahi atu.
I whakaputaina: (2019)

Human Lipoxygenase Pathway Gene Variation and Association with Markers of Subclinical Atherosclerosis in the Diabetes Heart Study
mā: Kathryn P. Burdon, me ētahi atu.
I whakaputaina: (2010)

Sphingomyelin synthase 2 is a positive regulator of the CSF1R-STAT3 pathway in pancreatic cancer-associated macrophage
mā: Shuhua He, me ētahi atu.
I whakaputaina: (2022)

Atherosclerosis in Juvenile Idiopathic Arthritis
mā: Ewa Jednacz, me ētahi atu.
I whakaputaina: (2012)

The role of phosphatidylcholine 34:1 in the occurrence, development and treatment of ulcerative colitis
mā: Tengjie Yu, me ētahi atu.
I whakaputaina: (2023)